221 related articles for article (PubMed ID: 10946896)
1. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas.
Persani L; Lania A; Alberti L; Romoli R; Mantovani G; Filetti S; Spada A; Conti M
J Clin Endocrinol Metab; 2000 Aug; 85(8):2872-8. PubMed ID: 10946896
[TBL] [Abstract][Full Text] [Related]
2. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Persani L; Borgato S; Lania A; Filopanti M; Mantovani G; Conti M; Spada A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3795-800. PubMed ID: 11502813
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.
Palos-Paz F; Perez-Guerra O; Cameselle-Teijeiro J; Rueda-Chimeno C; Barreiro-Morandeira F; Lado-Abeal J; ; Araujo Vilar D; Argueso R; Barca O; Botana M; Cabezas-Agrícola JM; Catalina P; Dominguez Gerpe L; Fernandez T; Mato A; Nuño A; Penin M; Victoria B
Eur J Endocrinol; 2008 Nov; 159(5):623-31. PubMed ID: 18694911
[TBL] [Abstract][Full Text] [Related]
5. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
6. Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas.
Calebiro D; Grassi ES; Eszlinger M; Ronchi CL; Godbole A; Bathon K; Guizzardi F; de Filippis T; Krohn K; Jaeschke H; Schwarzmayr T; Bircan R; Gozu HI; Sancak S; Niedziela M; Strom TM; Fassnacht M; Persani L; Paschke R
J Clin Invest; 2016 Sep; 126(9):3383-8. PubMed ID: 27500488
[TBL] [Abstract][Full Text] [Related]
7. Comparative proteomic analysis to dissect differences in signal transduction in activating TSH receptor mutations in the thyroid.
Krause K; Boisnard A; Ihling C; Ludgate M; Eszlinger M; Krohn K; Sinz A; Fuhrer D
Int J Biochem Cell Biol; 2012 Feb; 44(2):290-301. PubMed ID: 22074661
[TBL] [Abstract][Full Text] [Related]
8. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
Castro I; Lima L; Seoane R; Lado-Abeal J
Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991
[TBL] [Abstract][Full Text] [Related]
9. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3',5'-cyclic adenosine monophosphate signal generation.
Kosugi S; Okajima F; Ban T; Hidaka A; Shenker A; Kohn LD
Mol Endocrinol; 1993 Aug; 7(8):1009-20. PubMed ID: 7901757
[TBL] [Abstract][Full Text] [Related]
10. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells.
Porcellini A; Ruggiano G; Pannain S; Ciullo I; Amabile G; Fenzi G; Avvedimento EV
Oncogene; 1997 Aug; 15(7):781-9. PubMed ID: 9266964
[TBL] [Abstract][Full Text] [Related]
11. The 3',5'-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas.
Brunetti A; Chiefari E; Filetti S; Russo D
Endocrinology; 2000 Feb; 141(2):722-30. PubMed ID: 10650954
[TBL] [Abstract][Full Text] [Related]
12. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
[TBL] [Abstract][Full Text] [Related]
13. Adaptation of cAMP signaling system in SH-SY5Y neuroblastoma cells following expression of a constitutively active stimulatory G protein alpha, Q227L Gsalpha.
Jang IS; Juhnn YS
Exp Mol Med; 2001 Mar; 33(1):37-45. PubMed ID: 11322485
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells.
Fournes B; Monier R; Michiels F; Milgrom E; Misrahi M; Feunteun J
Oncogene; 1998 Feb; 16(8):985-90. PubMed ID: 9519872
[TBL] [Abstract][Full Text] [Related]
15. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
[TBL] [Abstract][Full Text] [Related]
16. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
[TBL] [Abstract][Full Text] [Related]
17. Lack of mutations in the TSHr and Gsalpha genes in TSHr antibody negative Graves' disease.
Elgadi A; Frisk T; Larsson C; Wallin G; Höög A; Zedenius J; Norgren S
Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):516-21. PubMed ID: 16235153
[TBL] [Abstract][Full Text] [Related]
18. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G
Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the mouse TSH receptor equivalent to human constitutively activating TSH receptor mutations also cause constitutive activity.
Neumann S; Krohn K; Chey S; Paschke R
Horm Metab Res; 2001 May; 33(5):263-9. PubMed ID: 11440271
[TBL] [Abstract][Full Text] [Related]
20. Enhanced functional activity in thyroid adenomas in vitro.
Poertl S; Kirner J; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():39-40. PubMed ID: 8980999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
